BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 18492096)

  • 1. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
    Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
    Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
    Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
    Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
    J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.
    Nyman H; Jantunen E; Juvonen E; Elonen E; Böhm J; Kosma VM; Enblad G; Karjalainen-Lindsberg ML; Leppä S
    Bone Marrow Transplant; 2008 Jul; 42(2):93-8. PubMed ID: 18391989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype".
    Kusumoto S; Kobayashi Y; Sekiguchi N; Tanimoto K; Onishi Y; Yokota Y; Watanabe T; Maeshima AM; Ishida T; Inagaki H; Matsuno Y; Ueda R; Tobinai K
    Am J Surg Pathol; 2005 Aug; 29(8):1067-73. PubMed ID: 16006802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Bone Marrow Transplant; 2008 Apr; 41(8):715-20. PubMed ID: 18195687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
    van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
    Kewalramani T; Zelenetz AD; Teruya-Feldstein J; Hamlin P; Yahalom J; Horwitz S; Nimer SD; Moskowitz CH
    Br J Haematol; 2006 Jul; 134(2):202-7. PubMed ID: 16759221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
    Jabłońska J; Jesionek-Kupnicka D
    Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.